This site is intended for UK healthcare professionals
Medscape UK Univadis Logo
Medscape UK Univadis Logo

Cyclizine hydrochloride


Oral formulations of cyclizine hydrochloride.

Drugs List

  • cyclizine 50mg tablets
  • Therapeutic Indications


    Prevention and treatment of nausea and vomiting including that associated with motion sickness, narcotic analgesics, the post operative period following general anaesthesia and radiotherapy (especially in breast cancer patients since cyclizine does not elevate prolactin levels).

    For the relief of vomiting and attacks of vertigo associated with Meniere's disease and other forms of vestibular disturbance.



    50mg, to be taken 1 or 2 hours before departure, up to three times a day.


    Children aged 12 to 18 years
    (See Dosage; Adult)

    Children aged 6 to 12 years
    25mg, to be taken 1 or 2 hours before departure, up to three times a day.

    Children 1 month to 6 years (unlicensed)
    0.5mg/kg to 1mg/kg to be taken 1 or 2 hours before departure, up to three times a day.
    Maximum of 25mg per dose.


    For oral use.


    Breastfeeding ( See Lactation section )


    Precautions and Warnings

    Children 1 month to 6 years of age ( see Dosage - Children )
    Pregnancy ( See Pregnancy section )

    Cyclizine, as with other anticholinergic agents should be used with caution and appropriate monitoring in the following:
    Obstructive disease of the gastrointestinal tract
    Prostatic hypertrophy
    Urinary retention
    Hepatic disease
    Renal impairment

    Cyclizine should be used with caution in patients with severe heart failure. In such patients, cyclizine may cause a fall in cardiac output associated with increases in heart rate, mean arterial pressure and pulmonary wedge pressure.

    May counteract the haemodynamic benefits of opioids and caution should be exercised in acute myocardial infarction.

    May cause drowsiness. If affected patients should not drive or operate machinery.
    Patients should avoid alcohol as additive effects of drowsiness and poor co-ordination may occur.
    As an antiemetic, cyclizine also makes toxicity from alcohol more dangerous.

    Contains lactose and should not be given to patients with lactose intolerance or glucose-galactose malabsorption syndrome.

    Cyclizine has been misused for its euphoric or hallucinatory effects.

    Use in Porphyria

    Contraindicated for use in porphyria

    Pregnancy and Lactation


    The manufacturer states that safety in pregnancy is not established. In the absence of any definitive human data, the use of cyclizine in pregnancy is not advised.

    Schaefer (2007) indicates cyclizine as an effective and safe treatment for nausea and vomiting in pregnancy.

    Briggs (2011) cites that cyclizine is teratogenic in animals but not in humans. No increased malformations were observed when used in 111 patients in the first trimester and no link to oral clefts has been found. A retrospective study found that significantly fewer infants with malformations were exposed to antihistamines/antiemetics in the first trimester compared with controls.
    On this body of evidence, cyclizine is indicated to be compatible with human pregnancy.

    An association between retrolental fibroplasia in premature infants has been reported with the use of antihistamines in the last 2 weeks of the pregnancy.

    The use of all medication in pregnancy should be avoided whenever possible; particularly in the first trimester. Non-drug treatments should also be considered. When essential, a medication with the best safety record over time should be chosen, employing the lowest effective dose for the shortest possible time. Polypharmacy should be avoided. Teratogens taken in the pre-embryonic period, often quoted as lasting until 14-17 days post-conception, are believed to have an all-or-nothing effect. Where drugs have a short half-life, and when the date of conception is certain, this may allow women to be reassured where drug exposure has occurred within this time frame. Further advice may be available from the UK National Teratology Information Service (NTIS) and through ToxBase, available via password on the internet ( ) or if this is unavailable at the backup site ( ).


    Contraindicated whilst breastfeeding as it is not known whether cyclizine or its metabolites are excreted in human milk. At the time of writing, no reports of its use during breastfeeding have been located.

    Neonates, infants born prematurely, those with low birth weight, those with an unstable gastrointestinal function or who have serious illnesses may require special consideration. For any infant, if a drug is prescribed to the nursing mother, it should be at the lowest practical dose and for the shortest time. When drug administration is unavoidable and breastfeeding is to continue, minimisation of exposure of the infant to the drug may sometimes be achieved by timing the maternal doses to just after a feeding episode. Infants exposed to drugs via breast milk should be monitored for unusual signs or symptoms. Interactions between the drug received by the infant from the mother's milk and medication prescribed for the infant should also be considered, for example, when the drug given to the infant may prevent metabolism of the drug received via breast milk.
    Specialist advice is available from the UK Drugs in Lactation Advisory Service at

    Effects on Ability to Drive and Operate Machinery

    As sedation is a potential side effect patients should not drive or operate machinery until they have determined their own response to treatment.

    Although there are no data available, patients should be cautioned that there may be additive effects with alcohol.


    Advise patients that cyclizine may cause drowsiness and if affected they should not drive or operate machinery.

    Patients should avoid alcohol as additive effects of drowsiness and poor co-ordination may occur.
    As an antiemetic, cyclizine also makes toxicity from alcohol more dangerous.

    Side Effects

    Dry mouth
    Dryness of nose
    Dry throat
    Blurred vision
    Urinary retention
    Sleep disturbances
    Extrapyramidal effects
    Hypersensitivity reactions
    Hepatic impairment
    Cholestatic jaundice
    Fixed drug eruption
    Psychomotor impairment
    Gastro-intestinal disturbances
    Blood disorders
    Muscle spasm
    Impaired consciousness
    Speech disturbances
    Allergic skin reactions
    Oculogyric crisis
    Aggravation of cardiac failure


    It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.

    The following number will direct the caller to the relevant local centre (0844) 892 0111

    Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( ) or if this is unavailable at the backup site ( ).

    Shelf Life and Storage

    Store below 25 degrees C.

    Further Information

    Last Full Review Date: June 2012

    Reference Sources

    Drugs During Pregnancy and Lactation: Treatment Options and Risk Assessment, 2nd edition (2007) ed. Schaefer, C., Peters, P. and Miller, R. Elsevier, London.

    Drugs in Pregnancy and Lactation: A Reference Guide to Fetal and Neonatal Risk, 9th edition (2011) ed. Briggs, G., Freeman, R. and Yaffe, S. Lippincott Williams & Wilkins, Philadelphia.

    Martindale: The Complete Drug Reference, 37th edition (2011) ed. Sweetman, S. Pharmaceutical Press, London.

    The Renal Drug Handbook. 3rd edition. (2009) ed. Ashley, C and Currie, Radcliffe Publishing Ltd, Abingdon.

    Summary of Product Characteristics: Cyclizine 50mg Tablets. Amdipharm UK Limited. Revised March 2015.

    NICE Evidence Services Available at: Last accessed: 18 August 2017

    Access the full UK drug database with a FREE Medscape UK Account
    It takes just a few minutes, and you’ll get unlimited access to information on over 11,000 UK drugs.
    Register for Free

    Already a member? Log in

    Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content

    FDB Logo

    FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.